logo.PNG
Ark Biopharmaceutical Presents Positive Results in Phase 3 AIRFLO Study of Ziresovir in RSV-Infected Hospitalized Infants at 12th International RSV Symposium
06. Oktober 2022 23:39 ET | Shanghai Ark Biopharmaceutical Co., Ltd.
SHANGHAI, China, Oct. 07, 2022 (GLOBE NEWSWIRE) -- Results from Shanghai Ark Biopharmaceutical Co., Ltd. (Ark Biopharmaceutical)’s successful Phase 3 study (AIRFLO) with the respiratory syncytial...
CocrystalPharmaInc.jpg
Cocrystal Pharma Announces Presentation of Preclinical Characterization Data of CC-42344 at the 6th ISIRV-AVG Conference
13. November 2018 11:50 ET | Cocrystal Pharma, Inc.
- Company’s novel, broad spectrum influenza antivirals specifically designed to be effective against all significant A strains of the influenza virus -  - CC-43244, Company’s lead molecule has...